---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015596"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:26:29.757070+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test

## Summary
- Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.
- Net loss improved to $8.5M from $10.4M YoY; cash & equivalents $5.6M at Dec 31, 2023.
- CMS finalized $950/test lab fee for kidneyintelX.dkd; NGS resumed claim payment.
- Targeting ~33% lower cash burn in Q3 FY2024 vs Q2; annualized burn under $23M.
- Published real-world evidence: 61% increase in kidney protective drug prescriptions after testing.

## SEC filing metadata
- accession: 0000950170-24-015596
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/0000950170-24-015596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/rnlx-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015596
- JSON: https://secwatch.observer/filing/0000950170-24-015596.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015596.txt

## Key facts
- Earnings Releases
  Renalytix plc reported second quarter ended December 31, 2023 results: revenue $0.7 million, net income Net loss was $8.5 million.
  - Period: second quarter ended December 31, 2023
  - Revenue: $0.7 million
  - Net income: Net loss was $8.5 million
  - Result: reported results
  source text: During the three months ended December 31, 2023, we recognized $0.7 million of revenue related to sales of KidneyIntelX.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/0000950170-24-015596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.